A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants

NCT06663436 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Diarrhoea

Interventions

BIOLOGICAL: altSonflex1-2-3 Dose A
BIOLOGICAL: altSonflex1-2-3 Dose B
BIOLOGICAL: altSonflex1-2-3 Dose C
BIOLOGICAL: TYPHIBEV
COMBINATION_PRODUCT: Infanrix hexa
BIOLOGICAL: MR-VAC

Sponsor

GlaxoSmithKline